DK2213680T3 - Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer - Google Patents

Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer

Info

Publication number: DK2213680T3
Authority: DK; Denmark
Prior art keywords: alkylated; natural; optionally; substituted; amino acid
Prior art date: 2006-08-09

Application number

DK10156101.7T

Other languages

English (en)

Inventor

Maria Vincenza Carriero

Rosa Mario De

Vincenzo Pavone

Original Assignee

Pharmaphelix S R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-09

Filing date

2007-07-19

Publication date

2013-05-06

2007-07-19 Application filed by Pharmaphelix S R L filed Critical Pharmaphelix S R L

2013-05-06 Application granted granted Critical

2013-05-06 Publication of DK2213680T3 publication Critical patent/DK2213680T3/da

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
230000012292 cell migration Effects 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000000144 pharmacologic effect Effects 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 7
125000004432 carbon atom Chemical group C* 0.000 abstract 6
229910052799 carbon Inorganic materials 0.000 abstract 3
230000002209 hydrophobic effect Effects 0.000 abstract 3
125000006165 cyclic alkyl group Chemical group 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001414 amino alcohols Chemical class 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK10156101.7T 2006-08-09 2007-07-19 Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer DK2213680T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT001607A ITMI20061607A1 (it)	2006-08-09	2006-08-09	Peptidi con attivita farmacologica
EP07786192A EP2049562B1 (en)	2006-08-09	2007-07-19	Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer

Publications (1)

Publication Number	Publication Date
DK2213680T3 true DK2213680T3 (da)	2013-05-06

Family

ID=38776401

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10156101.7T DK2213680T3 (da)	2006-08-09	2007-07-19	Peptider med farmakologisk aktivitet til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
DK07786192.0T DK2049562T3 (da)	2006-08-09	2007-07-19	Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK07786192.0T DK2049562T3 (da)	2006-08-09	2007-07-19	Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer

Country Status (22)

Country	Link
US (1)	US8354374B2 (da)
EP (3)	EP2230245B1 (da)
JP (1)	JP5384342B2 (da)
KR (1)	KR101464576B1 (da)
CN (1)	CN101501060B (da)
AT (1)	ATE544775T1 (da)
AU (1)	AU2007283150B2 (da)
BR (1)	BRPI0715407A2 (da)
CA (1)	CA2660183C (da)
CY (2)	CY1113941T1 (da)
DK (2)	DK2213680T3 (da)
ES (2)	ES2404052T3 (da)
HR (1)	HRP20130331T1 (da)
IL (1)	IL196929A (da)
IT (1)	ITMI20061607A1 (da)
ME (1)	ME02425B (da)
MX (1)	MX2009001452A (da)
PL (2)	PL2049562T3 (da)
PT (2)	PT2049562E (da)
RS (1)	RS52786B (da)
SI (2)	SI2213680T1 (da)
WO (1)	WO2008017372A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP3329A (en)	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
SG181797A1 (en)	2009-12-18	2012-07-30	Idenix Pharmaceuticals Inc	5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2013044500A1 (zh) *	2011-09-30	2013-04-04	Cheng Yun	丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
NZ702333A (en)	2012-05-03	2017-06-30	Zealand Pharma As	Gip-glp-1 dual agonist compounds and methods
MX356957B (es)	2012-07-23	2018-06-20	Zealand Pharma As	Analogos del glucagon.
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
AU2014345569B2 (en)	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
JP6989385B2 (ja)	2015-04-16	2022-01-05	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
ITUB20169928A1 (it) *	2016-01-12	2017-07-12	Medical And Biotechnological Services In Sigla M B S Srl	Formulazioni farmaceutiche per il trattamento del diabete
ITUB20169937A1 (it) *	2016-01-12	2017-07-12	Medical And Biotechnological Services In Sigla M B S Srl	Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
EP3231811A1 (en)	2016-04-11	2017-10-18	Istituto Nazionale Tumori Irccs "Fondazione G. Pascale"	Retro-inverso peptide inhibitors of cell migration, extracellular matrix and endothelial invasion by tumor cells
WO2017179647A1 (ja) *	2016-04-14	2017-10-19	Ｔａｏヘルスライフファーマ株式会社	アミロスフェロイド（ａｓｐｄ）結合阻害ペプチド、並びに評価及びスクリーニング方法
US20210324002A1 (en)	2018-09-28	2021-10-21	Nutcracker Therapeutics, Inc.	Tertiary amino lipidated cationic peptides for nucleic acid delivery
IT202200007754A1 (it)	2022-04-19	2023-10-19	Iridea S R L	Nuovi composti con attivita’ farmacologica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8202788A1 (es) *	1981-04-23	1982-02-16	Jorba Puigsubira Jose Ma	Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables
CA2094785A1 (en) *	1992-05-08	1993-11-09	Jean Gariepy	Metal chelating peptide
US20030009022A1 (en) *	1993-03-31	2003-01-09	Cadus Pharmaceutical Corporation	Methods and compositions for identifying receptor effectors
US6046167A (en)	1998-03-25	2000-04-04	University Of Cincinnati	Peptide YY analogs
US6388054B1 (en)	1998-08-20	2002-05-14	John M. Stewart	Anti-cancer compounds
JP4486187B2 (ja)	1998-10-27	2010-06-23	武田薬品工業株式会社	新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
DK174549B1 (da) *	2000-02-01	2003-05-26	Raaco Internat A S	Indretning til optagelse og fastholdelse af værktøjer
WO2001071342A2 (en) *	2000-03-23	2001-09-27	Novartis Ag	Identification of mast cell/basophil activation inhibitors
CA2404257A1 (en)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Novel protein, dna thereof and process for producing the same
US6689938B2 (en) *	2000-09-13	2004-02-10	Oklajoma Medical Research Foundation	Method for treatment of insulin resistance in obesity and diabetes
EP1365797B1 (en) *	2001-01-25	2007-05-02	Fondazione Centro San Raffaele Del Monte Tabor	Antibodies modulating the upa/upar interaction and uses thereof
US6815426B2 (en) *	2001-02-16	2004-11-09	E. I. Du Pont De Nemours And Company	Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085399A1 (fr)	2001-04-20	2002-10-31	Takeda Chemical Industries, Ltd.	Preparations contenant un peptide
EP1414849B1 (en) *	2002-01-29	2009-04-29	Posco	Immune-modulating peptide
US7267942B2 (en) *	2003-03-24	2007-09-11	The University Of Hong Kong	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
MXPA06014206A (es) *	2004-06-25	2007-02-14	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos.
US8143228B2 (en) *	2004-07-12	2012-03-27	Medical Research Fund Of Tel Aviv Sourasky Medical Center	Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
EP2799449A1 (en) *	2006-05-25	2014-11-05	Bayer Intellectual Property GmbH	Dimeric molecular complexes

2006
- 2006-08-09 IT IT001607A patent/ITMI20061607A1/it unknown
2007
- 2007-07-19 EP EP10156125A patent/EP2230245B1/en active Active
- 2007-07-19 ME MEP-2016-16A patent/ME02425B/me unknown
- 2007-07-19 US US12/376,465 patent/US8354374B2/en not_active Expired - Fee Related
- 2007-07-19 PT PT77861920T patent/PT2049562E/pt unknown
- 2007-07-19 JP JP2009523170A patent/JP5384342B2/ja not_active Expired - Fee Related
- 2007-07-19 SI SI200731220T patent/SI2213680T1/sl unknown
- 2007-07-19 BR BRPI0715407-0A patent/BRPI0715407A2/pt not_active IP Right Cessation
- 2007-07-19 CA CA2660183A patent/CA2660183C/en not_active Expired - Fee Related
- 2007-07-19 EP EP10156101A patent/EP2213680B1/en not_active Not-in-force
- 2007-07-19 PT PT101561017T patent/PT2213680E/pt unknown
- 2007-07-19 ES ES07786192T patent/ES2404052T3/es active Active
- 2007-07-19 HR HRP20130331TT patent/HRP20130331T1/hr unknown
- 2007-07-19 RS RS20130195A patent/RS52786B/sr unknown
- 2007-07-19 DK DK10156101.7T patent/DK2213680T3/da active
- 2007-07-19 DK DK07786192.0T patent/DK2049562T3/da active
- 2007-07-19 EP EP07786192A patent/EP2049562B1/en active Active
- 2007-07-19 MX MX2009001452A patent/MX2009001452A/es active IP Right Grant
- 2007-07-19 CN CN2007800292667A patent/CN101501060B/zh not_active Expired - Fee Related
- 2007-07-19 WO PCT/EP2007/006424 patent/WO2008017372A1/en not_active Ceased
- 2007-07-19 AT AT10156125T patent/ATE544775T1/de active
- 2007-07-19 KR KR1020097002560A patent/KR101464576B1/ko not_active Expired - Fee Related
- 2007-07-19 PL PL07786192T patent/PL2049562T3/pl unknown
- 2007-07-19 PL PL10156101T patent/PL2213680T3/pl unknown
- 2007-07-19 SI SI200731228T patent/SI2049562T1/sl unknown
- 2007-07-19 AU AU2007283150A patent/AU2007283150B2/en not_active Ceased
- 2007-07-19 ES ES10156101T patent/ES2406090T3/es active Active
2009
- 2009-02-05 IL IL196929A patent/IL196929A/en active IP Right Grant
2013
- 2013-04-23 CY CY20131100329T patent/CY1113941T1/el unknown
- 2013-05-29 CY CY20131100426T patent/CY1114014T1/el unknown

Also Published As

Publication number	Publication date
CA2660183C (en)	2016-09-27
IL196929A (en)	2016-02-29
WO2008017372A1 (en)	2008-02-14
EP2230245A1 (en)	2010-09-22
HK1136304A1 (en)	2010-06-25
ES2406090T3 (es)	2013-06-05
ME02425B (me)	2016-09-20
ATE544775T1 (de)	2012-02-15
CN101501060B (zh)	2012-11-07
KR101464576B1 (ko)	2014-12-04
PL2049562T3 (pl)	2013-07-31
ES2404052T3 (es)	2013-05-23
ITMI20061607A1 (it)	2008-02-10
RS52786B (sr)	2013-10-31
CY1113941T1 (el)	2016-07-27
IL196929A0 (en)	2009-11-18
AU2007283150B2 (en)	2012-11-29
SI2213680T1 (sl)	2013-06-28
KR20090051041A (ko)	2009-05-20
BRPI0715407A2 (pt)	2013-07-02
PT2213680E (pt)	2013-05-10
SI2049562T1 (sl)	2013-06-28
AU2007283150A1 (en)	2008-02-14
JP2010500298A (ja)	2010-01-07
EP2213680B1 (en)	2013-03-20
PT2049562E (pt)	2013-04-24
EP2049562B1 (en)	2013-02-27
EP2230245B1 (en)	2012-02-08
PL2213680T3 (pl)	2013-08-30
US20110230397A1 (en)	2011-09-22
CA2660183A1 (en)	2008-02-14
EP2213680A1 (en)	2010-08-04
CY1114014T1 (el)	2016-07-27
DK2049562T3 (da)	2013-04-15
HRP20130331T1 (hr)	2013-05-31
US8354374B2 (en)	2013-01-15
MX2009001452A (es)	2009-04-08
JP5384342B2 (ja)	2014-01-08
CN101501060A (zh)	2009-08-05
EP2049562A1 (en)	2009-04-22

Publication	Publication Date	Title
DK2049562T3 (da)	2013-04-15	Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
MA31997B1 (fr)	2011-01-03	Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
ECSP13013115A (es)	2014-06-30	Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales
MX382833B (es)	2025-03-13	Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar
WO2012164488A3 (en)	2014-01-23	New cosmetic or dermopharmaceutical topical use of a mixture of a ghk tripeptide and gqpr tetrapeptide
PH12013501213A1 (en)	2016-12-16	Cyclosporine analogue molecules modified at amino acid 1 and 3
BRPI0816405B8 (pt)	2021-05-25	complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
DE602006011099D1 (de)	2010-01-28	Verfahren zur herstellung von peptidderivaten
TW200833365A (en)	2008-08-16	Neuronal exocytosis inhibiting peptides
UY29004A1 (es)	2006-02-24	Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
BRPI0606301A2 (pt)	2009-07-07	processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos
EA201000327A1 (ru)	2010-10-29	Белок
PE20141199A1 (es)	2014-09-24	Depsipeptidos ciclicos como moduladores de calicreina 7
BRPI0408353A (pt)	2006-03-21	composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR112016013157A2 (pt)	2017-09-26	peptídeos resistentes à protease
AR055179A1 (es)	2007-08-08	Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
BRPI0413437A (pt)	2006-10-10	preparação de peptìdeos de somatostatina
DE602007013796D1 (de)	2011-05-19	Ausstossflüssigkeit und ausstossverfahren
ATE467643T1 (de)	2010-05-15	Peptide mit proliferationshemmender wirkung
WO2006119402A3 (en)	2007-02-22	C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
IN2013MU02758A (da)	2015-07-03
CO2020003870A2 (es)	2020-04-24	Método para la preparación de ácidos alfa haloalcanoicos quirales
ES447686A1 (es)	1977-06-16	Procedimiento para la preparacion de tripeptidos derivados de la l-prolina.
CU22988A3 (es)	2004-09-29	Amidas de ácidos fenilciclohexanocarboxílicos sustituidas con efecto inhibidor de la captación de adenosina
BR112014000466A2 (pt)	2017-02-21	polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos